Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus METATENSIN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus METATENSIN 4.
DEMI-REGROTON vs METATENSIN #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination